E Ink Corp. is a supplier of electronic paper display (EPD) technologies. Products made with E Ink's electronic ink are designed to possess a paper-like high contrast appearance, ultra-low power consumption, and a thin, light form. E Ink's technology is tailored for many consumer and industrial applications including handheld devices, watches, clocks, and public information and promotional signs.

E Ink

Amadeus Capital is a global technology investor that invests in technology companies at all stages, from seed to venture buyout; they also buy stakes from other investors or founders, to ensure that companies and entrepreneurs have the runway they need to succeed. They invest in a broad variety of sectors including enterprise and infrastructure software, consumer and business services, medical technology and healthcare IT, and cleantech and resource efficiency. It has the imagination to see where new businesses can be created and the technical insight, operational experience and global network to help entrepreneurs make their vision a reality. The Company was founded in 1997 and since has backed more than 130 companies and raised over $1bn for investment.

Amadeus Capital Partners

G. K. Goh Holdings originated from the creation by Mr Goh Geok Khim in 1979 of a Singapore stockbroking company. Following its listing in 1990, the group grew to become one of the most significant non-bank securities companies in Southeast Asia.   In 2005, the securities businesses were entirely sold. A part of the cash proceeds was returned to shareholders, while the balance was redeployed towards other investments. Group net assets amounted to S$313 million at the end of 2010.

G. K. Goh

The British Business Bank brings expertise and Government money to the smaller business finance markets. Understanding markets and smaller businesses’ finance needs allows us to design programmes to make finance markets work better, and investing alongside private sector investors maximises their impact and allows us to reach the full range of finance providers such as banks, leasing companies, venture capital funds and web-based platforms.

British Business Bank

Future Planet Capital is the global impact-led venture capital firm built to back growth companies from the world's top universities and research ecosystems. The group manages $380m for institutional investors and has invested in over 300 companies, with 60 successful exits. It's portfolio is built around breakthrough technologies solving global challenges in Climate, Health, Education, Sustainable Growth and Climate Change.

Future Planet Capital

M&G is an investment manager that puts people's investments to work to help them prosper. Their customers include individual savers and investors, members of pension schemes, and life insurance policyholders. They look for opportunities to invest, across a wide range of assets, on behalf of people who care how their money is invested.

M&G Investments

RT Partners is a boutique investment firm focused on UK investing in IP-rich technology, with a particular emphasis on bio-tech and genomics.

RT Partners

Verve Ventures is a European startup investment platform for qualified and institutional investors. Their fully digital platform enables private investors to build a diversified portfolio with investments starting at CHF/EUR 10'000. Since its launch in 2010, Verve Ventures has invested more than EUR 130 million in over 100 startups. Their community consists of 5’000 registered qualified private investors, family offices, and pension funds. Several institutional investors such as a large Swiss pension fund and numerous corporates also rely on their expertise to invest in promising startups. Verve Ventures is backed by Switzerland's third-largest bank, Zürcher Kantonalbank. They have a dedicated investment team based in Zurich, Lausanne, Berlin, Paris, and Cambridge, that screens thousands of startups each year and selects the top 1% after a rigorous due diligence process. They are reshaping the European venture capital landscape and granting investors superior access to this traditionally intransparent asset class. They source the best deals, and structure rounds, and enable their investors to participate in competitive startup deals.

Verve Ventures

Nuclera

Nuclera is a US and UK-based biotechnology company driven by the mission to better human health by making proteins accessible.  Nuclera is enabling life science researchers to obtain active proteins from DNA in 48 hours through its benchtop eProtein DiscoveryTM platform.  Using Nuclera’s system scientists can automate construct screening to inform off-platform protein scale up, delivering reliable protein in-hand (µg-mg amounts) in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system.

<div><p>Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered to take control of biology through streamlined access to a next-day supply of proteins and genes.</p></div>

Enabling supply of biologically safe tissues and organs using next-gen printing tech

Bioprinting

<div>
  <p>
    Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered to take control of biology through streamlined access to a next-day supply of proteins and genes.
  </p>
</div>


<div>
  <p>
    3D Bioprinting Solutions is a biotechnological research laboratory that develops and produces 3D bioprinters and bioprinting materials.
  </p>
</div>


3D Bioprinting Solutions

<div>
  <p>
    3Dynamic Systems
  </p>
</div>


3Dynamic Systems

<div>
  <p>
    A.D.A.M. (Advanced Development of Additive Manufacturing) is a biotech company that provides 3D-bioprinting services on demand. A.D.A.M. uses its proprietary 3D-printing technology and patented materials to manufacture bioresorbable and biodegradable patient-specific implants (primarily, bone implants). By designing and building an on-demand tissue manufacturing solution, we have been pioneering this technology as a service model to effectively address a complex problem. The business model will allow patients to have their tissue modelled – using the MRI/CAT scans stored on the digital platform – and, subsequently, 3D-printed and implanted in certified clinics. We reached our main achievement to date in August, as the FDA responded to our Q-Sub (Pre-Submission) confirming our 510(k) regulatory path eligibility. This response means that no human trials and required and a decrease in time to market from 5 years to 1.5-2 years.    Additionally, we have been accepted to join Technology Incubation Program at University of Connecticut in Farmington, CT. We have just moved our main office there as TIP offers state of the art research facilities and resources to its member companies. Our intention is to complete the required animal studies there.    Finally, we have secured our lead investor for the upcoming Series A round.
  </p>
</div>


A.D.A.M.

<div>
  <p>
    Advanced BioMatrix is a leader in the life science of three-dimensional (3D) applications for tissue culture, cell assay, bioprinting, and cell proliferation. The company's products are recognized as the standard for purity, functionality, and consistency. Advanced BioMatrix has extensive expertise in production, isolation, purification, lyophilization, cell culture, and testing of proteins, adhesion peptides, attachment factors, bio-inks, substrate rigidity, and other 3D matrix products. Their expertise and knowledge are being employed to assure that their products are of the highest quality, consistent from lot to lot, and easy to use for research customers. The company is located in the San Diego region – one of the world’s largest life science and biotechnology clusters. Advanced BioMatrix has been manufacturing and delivering high-quality products for research uses and applications for over 10 years. Advanced BioMatrix transforms science to a new level of discovery by providing advanced technologies through innovative 3D matrix products.
  </p>
</div>


Advanced Biomatrix

<div>
  <p>
    Advanced Solutions Life Sciences provides solutions for living organisms, molecular biology, and biotechnology.
  </p>
</div>


Advanced Solutions Life Sciences

3D printing enables bioprinting devices, which rely on a similar design and operating model

Startups in this hub are able to customize the bioprinted models to suit each patient

AI/ML is used in the design and optimization of 3D models that can be bioprinted

Developing and selling bioprinter devices that can be used by hospitals, research institutes, and other organizations seeking to print biological substitutes and materials.

Nuclera

Bioprinting

Key stats

EDGE Insights

Print your heart out: Bioprinting and the future of organs

Company Brief

Funding

Investors

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless